Published in Cancer Weekly, February 13th, 2007
The product divestitures are not material to the transaction.
"We're pleased to receive FTC clearance and move closer to becoming the world's leader in generic injectable pharmaceuticals," said Christopher B. Begley, CEO, Hospira. "Following the combination of our companies, we will be even better positioned to help...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.